Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome.

MLA

Brittney L Dickey, et al. “Oral Secretory Leukocyte Protease Inhibitor (SLPI): Associations with Oropharyngeal Cancer and Treatment Outcome.” PLoS ONE, vol. 16, no. 7, Jan. 2021, p. e0254161. EBSCOhost, https://doi.org/10.1371/journal.pone.0254161.

APA

Brittney L Dickey, Bradley Sirak, Laura Martin-Gomez, Richard R Reich, Martha Abrahamsen, Kimberly Isaacs-Soriano, Christine H Chung, & Anna R Giuliano. (2021). Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome. PLoS ONE, 16(7), e0254161. https://doi.org/10.1371/journal.pone.0254161

Chicago

Brittney L Dickey, Bradley Sirak, Laura Martin-Gomez, Richard R Reich, Martha Abrahamsen, Kimberly Isaacs-Soriano, Christine H Chung, and Anna R Giuliano. 2021. “Oral Secretory Leukocyte Protease Inhibitor (SLPI): Associations with Oropharyngeal Cancer and Treatment Outcome.” PLoS ONE 16 (7): e0254161. doi:10.1371/journal.pone.0254161.